RHUMAB- |
R-435 |
FKB-238 |
12-IGG1 |
BS-503A |
HLX-04 |
BEVACIZUMAB |
BEVACIZUMAB BETA |
RHUMAB-VEGF |
BI 695502 |
RG-435 |
AVASTIN |
AVA-1 |
HLX04 |
ANTIVEGF |
drugbank:00112 |
chembl:CHEMBL1201583 |
chemidplus:216974-75-3 |
pubchem.compound:135329020 |
rxcui:253337 |
FDA Approval | approved |
Drug Class | monoclonal antibody |
Drug Indications | antineoplastic agent |
Drug Categories | serum globulins |
FDA Approval | Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma |
Drug Class | Therapeutic Antibodies |
Year of Approval | 2004 |
Drug Class | antineoplastic agents |
Drug Categories | antineoplastic agents, immunological |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | experimental unapproved treatments for covid-19 |
Drug Categories | immunosuppressive agents |
Drug Categories | vascular endothelial growth factor inhibitor |
Drug Categories | vascular endothelial growth factor inhibitors |
Drug Categories | vascular endothelial growth factor-directed antibody interactions |
n/a |
n/a |
antibody (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Avastin |
Novel drug target | Established target |
Notes |
BEVACIZUMAB | DrugBank Drug Name |
216974-75-3 | CAS Number |
Avastin | Drug Brand |
Drug Type | biotech |
Drug Groups | approved |
Drug Groups | investigational |
BEVACIZUMAB | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 2004 |
BEVACIZUMAB | Generic Name |
AVASTIN | Trade Name |
Drug Class | Therapeutic Antibodies |
FDA Approval | Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma |
Drug Indications | antineoplastic agent |
Drug Class | monoclonal antibody |
FDA Approval | approved |
C2039 | NCI drug code |
BEVACIZUMAB | Primary Drug Name |
BEVACIZUMAB | Drug Generic Name |
AVASTIN | Drug Trade Name |
D04KBL | TTD Drug ID |